Week 219: Switching chemo

Written by Lars Haakon Soraas
03
Nov

Week 219 in the war on lung cancer has passed. Here are the highlights:

  • We decided to switch chemo from the low dose carboplatin and gemcitabine combination to nab-paclitaxel. The reason is lack of sufficient signs that the combination of carboplatin and gemcitabine was effective. We have been tracking the tumor markers CEA and NSE and, unfortunately, there was no clear downward trend in these after Dyanne started carbo+gem. On the contrary, the last week’s measurements showed us these markers both were increasing. The charts are pasted in at the bottom of this post.
  • Dyanne has this week done a new CT scan. We should get the results in the coming week.
  • Dyanne will also do an MR scan of the brain this coming week. We cross our fingers it gives us good news.
  • Dyanne has been a bit fatigued this week, in particular after the infusion of nab-paclitaxel. This is quite as expected, but, of course, still not very fun.

In other news, we can mention that we are looking into joining a trial in New York. Several stars need to align for her to be able to participate in the trial. Blood values need to be in range and the MR scan needs to be good. We cross our fingers that all works out and that she will be able to join the trial.

We hope everyone has had a good week.

CEA: transient jump, then continued climbing
NSE: transient jump, a bit decline, then further increase

Follow this blog

Get every new post delivered right to your inbox.